New hope for Cushing's patients with high blood pressure

NCT ID NCT07247162

Not yet recruiting Disease control Sponsor: RECORDATI GROUP Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a drug called osilodrostat in 63 adults with Cushing's syndrome and high blood pressure. The goal is to see if it can safely lower blood pressure by reducing cortisol levels. Participants will take the drug or a placebo for 30 weeks, with doses adjusted based on response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Osilodrostat
What this could lead to: If successful, this could provide a new treatment option to control blood pressure in people with Cushing's syndrome.
What could go wrong: This is a small, early-stage trial with only 63 participants. The drug may not work as expected or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUSHING SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal gland hyperfunction Cushing syndrome ectopic ACTH secretion syndrome hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUSHING SYNDROME HYPERCORTISOLEMIA HYPERTENSION

More trials for these conditions

Other studies related to the condition(s) this trial covers.